ARCT
Price
$7.21
Change
-$0.12 (-1.64%)
Updated
Feb 5, 02:22 PM (EDT)
Capitalization
208.28M
25 days until earnings call
Intraday BUY SELL Signals
BDTX
Price
$2.23
Change
-$0.16 (-6.69%)
Updated
Feb 5, 02:27 PM (EDT)
Capitalization
136.17M
41 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARCT vs BDTX

Header iconARCT vs BDTX Comparison
Open Charts ARCT vs BDTXBanner chart's image
Arcturus Therapeutics Holdings
Price$7.21
Change-$0.12 (-1.64%)
Volume$738
Capitalization208.28M
Black Diamond Therapeutics
Price$2.23
Change-$0.16 (-6.69%)
Volume$100
Capitalization136.17M
ARCT vs BDTX Comparison Chart in %
ARCT
Daily Signal:
Gain/Loss:
BDTX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ARCT vs. BDTX commentary
Feb 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a Hold and BDTX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 05, 2026
Stock price -- (ARCT: $7.33 vs. BDTX: $2.39)
Brand notoriety: ARCT and BDTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 82% vs. BDTX: 105%
Market capitalization -- ARCT: $208.28M vs. BDTX: $136.17M
ARCT [@Biotechnology] is valued at $208.28M. BDTX’s [@Biotechnology] market capitalization is $136.17M. The market cap for tickers in the [@Biotechnology] industry ranges from $119.38B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whileBDTX’s FA Score has 0 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • BDTX’s FA Score: 0 green, 5 red.
According to our system of comparison, BDTX is a better buy in the long-term than ARCT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 4 TA indicator(s) are bullish while BDTX’s TA Score has 4 bullish TA indicator(s).

  • ARCT’s TA Score: 4 bullish, 5 bearish.
  • BDTX’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, BDTX is a better buy in the short-term than ARCT.

Price Growth

ARCT (@Biotechnology) experienced а -0.54% price change this week, while BDTX (@Biotechnology) price change was -7.00% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.81%. For the same industry, the average monthly price growth was +0.47%, and the average quarterly price growth was +32.90%.

Reported Earning Dates

ARCT is expected to report earnings on Mar 02, 2026.

BDTX is expected to report earnings on Mar 18, 2026.

Industries' Descriptions

@Biotechnology (-3.81% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARCT($208M) has a higher market cap than BDTX($136M). ARCT YTD gains are higher at: 19.576 vs. BDTX (-1.646). BDTX has higher annual earnings (EBITDA): 12.2M vs. ARCT (-60.46M). ARCT has more cash in the bank: 180M vs. BDTX (136M). BDTX has less debt than ARCT: BDTX (19.7M) vs ARCT (26M). ARCT has higher revenues than BDTX: ARCT (85.1M) vs BDTX (70M).
ARCTBDTXARCT / BDTX
Capitalization208M136M153%
EBITDA-60.46M12.2M-496%
Gain YTD19.576-1.646-1,189%
P/E RatioN/A6.46-
Revenue85.1M70M122%
Total Cash180M136M132%
Total Debt26M19.7M132%
FUNDAMENTALS RATINGS
ARCT vs BDTX: Fundamental Ratings
ARCT
BDTX
OUTLOOK RATING
1..100
7765
VALUATION
overvalued / fair valued / undervalued
1..100
56
Fair valued
48
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9646
PRICE GROWTH RATING
1..100
6462
P/E GROWTH RATING
1..100
9999
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BDTX's Valuation (48) in the null industry is in the same range as ARCT (56) in the Pharmaceuticals Major industry. This means that BDTX’s stock grew similarly to ARCT’s over the last 12 months.

BDTX's Profit vs Risk Rating (100) in the null industry is in the same range as ARCT (100) in the Pharmaceuticals Major industry. This means that BDTX’s stock grew similarly to ARCT’s over the last 12 months.

BDTX's SMR Rating (46) in the null industry is somewhat better than the same rating for ARCT (96) in the Pharmaceuticals Major industry. This means that BDTX’s stock grew somewhat faster than ARCT’s over the last 12 months.

BDTX's Price Growth Rating (62) in the null industry is in the same range as ARCT (64) in the Pharmaceuticals Major industry. This means that BDTX’s stock grew similarly to ARCT’s over the last 12 months.

BDTX's P/E Growth Rating (99) in the null industry is in the same range as ARCT (99) in the Pharmaceuticals Major industry. This means that BDTX’s stock grew similarly to ARCT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTBDTX
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 15 days ago
79%
Bullish Trend 15 days ago
79%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
82%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ARCT
Daily Signal:
Gain/Loss:
BDTX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SVBT60.250.50
+0.84%
SVB&T Corporation
ACBD0.10N/A
N/A
Annabidiol Corp.
CMPRF2.33N/A
N/A
Gentera Sab De CV
RPGHF1.69N/A
N/A
RPMGLOBAL HLDGS LTD.
GXYEF5.29-0.34
-5.97%
Galaxy Entertainment Group, Ltd.

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been closely correlated with VTGN. These tickers have moved in lockstep 79% of the time. This A.I.-generated data suggests there is a high statistical probability that if ARCT jumps, then VTGN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
+0.14%
VTGN - ARCT
79%
Closely correlated
-3.20%
RZLT - ARCT
79%
Closely correlated
-7.62%
MREO - ARCT
78%
Closely correlated
-2.73%
QNCX - ARCT
75%
Closely correlated
+9.28%
LEGN - ARCT
73%
Closely correlated
-0.06%
More

BDTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BDTX has been closely correlated with ARCT. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if BDTX jumps, then ARCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BDTX
1D Price
Change %
BDTX100%
-5.16%
ARCT - BDTX
66%
Closely correlated
+0.14%
BCAB - BDTX
64%
Loosely correlated
+11.06%
VTGN - BDTX
63%
Loosely correlated
-3.20%
CRBU - BDTX
62%
Loosely correlated
+3.85%
MREO - BDTX
61%
Loosely correlated
-2.73%
More